QHSLab AI Stock Analysis
Want to see USAQ full AI Analyst Report?
QHSLab (USAQ) AI Stock Analysis
QHSLab
(Other OTC:USAQ)
The score is supported primarily by a strong, low-debt balance sheet and low P/E ratio. These strengths are offset by negative cash flow, weakening earnings momentum, and mixed technical conditions, including negative MACD and trading below the 200-day moving average.
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,146
- Price to Earnings (P/E)
- 9.0
- Beta (1Y)
- 1.93
- Revenue Growth
- 13.13%
- EPS Growth
- ―
- Country
- US
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops...
QHSLab Financial Statement Overview
Summary
Strong balance sheet with minimal debt, positive equity, and 51.2% ROE supports the score. However, declining earnings momentum, negative EBIT, and approximately $237,000 of negative operating and free cash flow materially reduce financial quality.
Income Statement
72PositiveBalance Sheet
80PositiveCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.96M | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Gross Profit | 1.98M | 1.81M | 1.36M | 793.61K | 619.52K | 670.75K |
| EBITDA | 571.66K | 785.56K | 352.39K | -91.29K | -434.60K | -487.63K |
| Net Income | 437.55K | 457.42K | -259.24K | -468.36K | -996.00K | -770.18K |
Balance Sheet | ||||||
| Total Assets | 1.75M | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Cash, Cash Equivalents and Short-Term Investments | 190.46K | 636.16K | 157.17K | 51.58K | 178.69K | 286.86K |
| Total Debt | 97.82K | 20.00K | 1.72M | 1.78M | 1.68M | 1.30M |
| Total Liabilities | 247.11K | 546.08K | 2.41M | 2.06M | 1.88M | 1.38M |
| Stockholders Equity | 1.51M | 1.62M | -607.76K | -375.62K | 76.25K | 824.07K |
Cash Flow | ||||||
| Free Cash Flow | -236.96K | 178.12K | 142.44K | -159.63K | -388.11K | -509.31K |
| Operating Cash Flow | -236.96K | 178.12K | 142.44K | -159.63K | -350.99K | -354.74K |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -37.12K | -154.57K |
| Financing Cash Flow | 269.03K | 300.87K | -36.85K | 32.52K | 279.95K | 701.82K |
QHSLab Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.35, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.60 is Neutral, neither overbought nor oversold. The STOCH value of 52.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 43 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksQHSLab Peers Comparison
Overall Rating
USAQ65Neutral
NUWE47Neutral
AEMD44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $5.51M | 8.97 | 28.18% | ― | 13.13% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $2.65M | -0.00 | -408.34% | ― | 10.28% | 95.85% | |
| 44Neutral | $8.49M | -0.50 | -141.22% | ― | ― | 90.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| USAQ | QHSLab, Inc. | 0.37 | 0.20 | 124.54% | |
| NUWE | Nuwellis, Inc. | 4.90 | -767.48 | -99.37% | |
| AEMD | Aethlon | 5.29 | -14.96 | -73.88% | |
| BBLG | Bone Biologics Corp | 0.33 | -1.30 | -80.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
